ESMO Asia 2023 | Asian subgroup analyses of ARASENS, J-ROCK and PREVAIL in prostate cancer

Deborah Mukherji, MBBS,FRCP, Clemenceau Medical Center, Dubai, UAE, outlines several studies that can contribute to our understanding of responses to different prostate cancer treatments in Asian subgroups. The Phase III ARASESNS study (NCT02799602) analysed treatment outcomes, toxicity responses and efficacy of darolutamide (DARO) with androgen-deprivation therapy (ADT) and docetaxel (DOC) in Chinese patients, whilst the J-ROCK study (NCT04034095) analysed different treatment responses in Japanese patients. Finally, Dr Mukherji states it will be interesting to see the Asian subgroup analysis results of the long-standing PREVAIL study (NCT01212991), whose data led to enzalutamide’s approval (ENZA), and how this alters long-term survival and our options for subsequent lines of therapy. The acquisition and analysis of this subpopulation data is important in our understanding of ethnic genetics’ interactions with treatments and will lead to better tailoring of this treatment in future. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.